



New Insights in Tumor-Infiltrating Lymphocytes

Guest Editors:

Dr. Serena Pellegatta

Unit of Immunotherapy of Brain Tumors, Department of Molecular Neuro-Oncology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133 Milan, Italy

Dr. Natalia Di Ianni

Unit of Immunotherapy of Brain Tumors, Department of Molecular Neuro-Oncology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133 Milan, Italy

Deadline for manuscript submissions:

closed (31 May 2023)

Message from the Guest Editors

We are living in an era where single-cell and multi-omics technologies are holding the potential to revolutionize the way to characterize the immune cells within the microenvironment and study their diversity, clonal distribution, pathways, and crosstalk. Tumor-infiltrating lymphocytes (TILs) are deserving of particular attention because they can be used as direct treatment mediators exerting an effective antitumor activity with low side effects per se. However, within the microenvironment, TILs engaged in tumor cell elimination become dysfunctional.

In light of this very important clinical objective, we need your innovative and original contribution to capture new insights in:

- Prognostic significance of TILs in solid cancers;
- Dysfunction in the relationship with the interaction with the microenvironment;
- Potential therapeutic reprogrammability;
- Identification of accessible markers to predict the functionality of TILs and/or their reprogramming.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI